CDK4 and esophageal cancer: Pyrotinib treatment reduced the cyclin D1 and cyclin-dependent kinase 4 (CDK4) levels for increasing G0/G1 arrest, resulting in the enhanced anti-proliferation effects of radiotherapy in esophageal cancer cells (Lian et al., 2020).